ABOS - Company ID 0001576885
The table below shows Acumen Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $21.11M | $27.81M | $16.48M | $21.97M | $37.13M | $25.27M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.70M |
| $4.75M |
| $4.67M |
| $4.54M |
| $4.63M |
| $5.10M |
| Operating income | -$25.81M | -$32.56M | -$21.15M | -$26.51M | -$41.75M | -$30.37M |
| Income tax | - | - | - | - | - | - |
| Net income | -$25.37M | -$32.72M | -$20.74M | -$26.45M | -$40.95M | -$28.80M |
| EPS (diluted) | -$0.35 | -$0.45 | -$0.33 | -$0.44 | -$0.68 | -$0.48 |